Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE007 (JPN) (Dr. Dubois)
· consented 2022-05-29
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
severe
assessed
2026-08-18
Grade 3 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2022-07-13 (study day 28); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Dyspnoea — outcome: UNKNOWN; onset 2022-09-18 (study day 95); relationship: N
moderate
assessed
2026-08-18
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-28 (study day 105); relationship: N
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-23 (study day 130); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 148); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-11 (study day 149); relationship: Y
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.